Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study

Ophthalmology

Volumn 123, Issue 5, 2016, Pages 1101-1111

  Larsen, Michael ^a   Waldstein, Sebastian M ^b   Boscia, Francesco ^c   Gerding, Heinrich ^d,j   Monés, Jordi ^e   Tadayoni, Ramin ^f   Priglinger, Siegfried ^g   Wenzel, Andreas ^h   Barnes, Elizabeth ^h   Pilz, Stefan ^h   Stubbings, William ^h   Pearce, Ian ⁱ  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF SASSARI   (Italy)

^d Klinik Pallas   (Switzerland)

^e CENTRO MÉDICO TEKNON   (Spain)

^f HÔPITAL LARIBOISIÈRE   (France)

^g UNIVERSITY OF MUNICH   (Germany)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^j UNIVERSITY OF MÜNSTER   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANXIETY; BACKACHE; BLEPHARITIS; BLURRED VISION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONJUNCTIVAL HEMORRHAGE; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; EYE DISCOMFORT; EYE PAIN; FEMALE; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; HYPHEMA; INFLUENZA; INJECTION SITE PAIN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOWER RESPIRATORY TRACT INFECTION; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA HEMORRHAGE; RETINA ISCHEMIA; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; VISUAL ACUITY; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETINAL VEIN OCCLUSION; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PRECISION MEDICINE; PROSPECTIVE STUDIES; RANIBIZUMAB; RETINAL VEIN OCCLUSION; SINGLE-BLIND METHOD; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84958214819     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2016.01.011     Document Type: Conference Paper

References (32)

1. S. Rogers, R.L. McIntosh, N. Cheung, and et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia Ophthalmology 117 2010 313 319e1
2. R.L. McIntosh, S.L. Rogers, L. Lim, and et al. Natural history of central retinal vein occlusion: an evidence-based systematic review Ophthalmology 117 2010 1113 1123e15
3. T. Braithwaite, A.A. Nanji, K. Lindsley, and P.B. Greenberg Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion Cochrane Database Syst Rev 5 2014 CD007325
4. R.J. Petrella, J. Blouin, B. Davies, and M. Barbeau Incidence and characteristics of patients with visual impairment due to macular edema secondary to retinal vein occlusion in a representative Canadian cohort J Ophthalmol 2012 2012 723169
5. H. Gerding, J. Mones, R. Tadayoni, and et al. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel Br J Ophthalmol 99 2015 297 304
6. R.A. Adelman, A.J. Parnes, S. Bopp, and et al. Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study Biomed Res Int 2015 2015 870987
7. R. Channa, M. Smith, and P.A. Campochiaro Treatment of macular edema due to retinal vein occlusions Clin Ophthalmol 5 2011 705 713
8. P.A. Campochiaro Anti-vascular endothelial growth factor treatment for retinal vein occlusions Ophthalmologica 227 Suppl 1 2012 30 35
9. D.M. Brown, P.A. Campochiaro, R.P. Singh, and et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133e1
10. P.A. Campochiaro, D.M. Brown, C.C. Awh, and et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 2011 2041 2049
11. J.S. Heier, P.A. Campochiaro, L. Yau, and et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial Ophthalmology 119 2012 802 809
12. European Medicines Agency. Assessment report. Lucentis. EMA/392690/2011 2011. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Assessment-Report---Variation/human/000715/WC500107807.pdf. Accessed May 5, 2015.
13. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report Ophthalmology 102 1995 1425 1433
14. C. Simader, M. Ritter, M. Bolz, and et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration Ophthalmology 121 2014 1237 1245
15. P. Kolar Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data J Ophthalmol 2014 2014 724780
16. M.S. Stem, N. Talwar, G.M. Comer, and J.D. Stein A longitudinal analysis of risk factors associated with central retinal vein occlusion Ophthalmology 120 2013 362 370
17. D.S. Boyer, A.N. Antoszyk, C.C. Awh, and et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration Ophthalmology 114 2007 246 252
18. S.B. Bressler, H. Qin, R.W. Beck, and et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab Arch Ophthalmol 130 2012 1153 1161
19. P.K. Kaiser, D.M. Brown, K. Zhang, and et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results Am J Ophthalmol 144 2007 850 857
20. T.A. Williams, and C.P. Blyth Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12 Eye (Lond) 25 2011 1617 1621
21. L. Arias, F. Armada, J. Donate, and et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss Eye (Lond) 23 2009 326 333
22. D.M. Brown, Q.D. Nguyen, D.M. Marcus, and et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE Ophthalmology 120 2013 2013 2022
23. A. Oliver-Fernandez, J. Bakal, S. Segal, and et al. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration Can J Ophthalmol 40 2005 313 319
24. A.B. Thach, L. Yau, C. Hoang, and L. Tuomi Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials Ophthalmology 121 2014 1059 1066
25. D.M. Brown, J.S. Heier, W.L. Clark, and et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study Am J Ophthalmol 155 2013 429 437e7
26. European Medicines Agency Summary of product characteristics. Lucentis 10 mg/ml solution for injection 2014 Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000715/WC500043546.pdf Accessed May 5, 2015
27. P.A. Campochiaro, R. Sophie, J. Pearlman, and et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study Ophthalmology 121 2014 209 219
28. P.A. Campochiaro, C.C. Wykoff, M. Singer, and et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study Ophthalmology 121 2014 2432 2442
29. J.F. Korobelnik, D.V. Do, U. Schmidt-Erfurth, and et al. Intravitreal aflibercept for diabetic macular edema Ophthalmology 121 2014 2247 2254
30. J.S. Heier, W.L. Clark, D.S. Boyer, and et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study Ophthalmology 121 2014 1414 1420e1
31. S.S. Hayreh, P.A. Podhajsky, and M.B. Zimmerman Natural history of visual outcome in central retinal vein occlusion Ophthalmology 118 2011 119 133e1-2
32. S.G. Priglinger, A.H. Wolf, T.C. Kreutzer, and et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial Retina 27 2007 1004 1012